In July 2020, remimazolam, a novel short-acting drug, was approved in the US for procedural sedation in adults (1). Like midazolam (a common anesthetic adjunct), remimazolam is a benzodiazepine and operates by modulating γ-aminobutyric acid (GABA) receptor activity to induce…
